Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04510636
Title Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

Hodgkin's lymphoma

Therapies

Bendamustine + Pembrolizumab

Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.